WASHINGTON: People who received Johnson & Johnson’s Covid-19 vaccine may benefit from a booster dose of Pfizer or Moderna, preliminary results of a US study published Wednesday showed.
The study, funded by the National Institutes of Health (NIH), was eagerly awaited in the United States because it looked at the possibility of “mixing” vaccines — using a different vaccine than the initial doses for the booster shot — which is not currently allowed in the country.
The study was conducted on 458 adults who had been vaccinated with one of three US-approved brands (Pfizer, Moderna or J&J) for at least 12 weeks.
These three groups were each divided into three new groups to receive one of the available vaccines as a booster. The nine groups consisted of about 50 people each.
Researchers then analyzed antibody levels 15 days after the booster shot.
For people originally inoculated with J&J, antibody levels were four times higher after a J&J booster, 35 times higher after a Pfizer booster and 76 times higher after a Moderna booster.
And antibody levels for those who had originally received Moderna shots were higher “irrespective of the booster vaccine administered,” when compared with those who had initially received Pfizer or J&J, the study said.
Additionally, “no safety concerns were identified” after booster doses were administered, it found.
The study, which has not yet been peer-reviewed, has several limitations, however.
The number of participants was small, and the immune response could evolve over time, beyond the 15 days observed during the study.
“Important not to get too carried away with the findings,” tweeted Peter Hotez, a professor at Baylor College of Medicine.
Results from trials on a second J&J booster shot conducted by the company itself were “impressive,” he said.
The NIH study should fuel discussions by a US Food and Drug Administration (FDA) expert committee, which is scheduled to consider applications for a booster dose from Moderna and J&J on Thursday and Friday, respectively.
A booster from Pfizer has already been approved in the United States for certain populations, such as people aged 65 or older, adults with high-risk medical conditions and those in jobs where they are frequently exposed to the coronavirus.
Moderna or Pfizer booster works better for people vaccinated with J&J: study
https://arab.news/bjy5f
Moderna or Pfizer booster works better for people vaccinated with J&J: study
- The study was conducted on 458 adults who had been vaccinated with one of three US-approved brands (Pfizer, Moderna or J&J) for at least 12 weeks.
Obamacare health subsidy to end as US Senate rejects dueling remedies
- Senate rejects Republican and Democratic health care proposals
- Democratic plan sought subsidy extension; Republicans offered to boost health savings accounts
WASHINGTON: The US Senate on Thursday rejected competing proposals by Republicans and Democrats to address a looming health care crisis, leaving some 24 million Americans vulnerable to significantly higher insurance premiums beginning on January 1 when a federal subsidy expires.
Barring any late breakthroughs, Congress will begin an end-of-year holiday recess sometime next week and not return until January 5, after new premiums are locked in for those who had relied on the Affordable Care Act enhanced subsidy.
In back-to-back votes largely along party lines, Democrats and Republicans blocked each other’s bill.
The House of Representatives might attempt to pass some sort of legislation next week, which has not yet been unveiled. Even if it were to pass, Senate Democrats, and possibly some Republicans, would oppose it and they could use their votes to kill that effort.
“After today’s vote, the American health care crisis is 100 percent on their shoulders,” Senate Democratic leader Chuck Schumer said of Republicans.
Senate Republican leader John Thune dismissed the Democratic bill as “a political messaging exercise” and said “Republicans are ready to get to work. I’m not sure yet that Democrats are interested.”
The bitter battle in Congress has left some Americans uncertain over renewing their health insurance under the federal health care program.
The percentage of returning customers in the Obamacare exchanges is slightly down from a year ago, with the government reporting 19.9 percent of people enrolled this year opting to renew their plans so far, down from 20.5 percent this time last year.
The Republican bill by US Senators Bill Cassidy of Louisiana and Mike Crapo of Idaho would have sent up to $1,500 to individuals earning less than 700 percent of the federal poverty level — about $110,000 for an individual or $225,000 for a family of four in 2025. Those funds could not be used for abortion or gender transition procedures and would require verification of beneficiaries’ immigration or citizenship status — provisions Democrats reject.
The Democratic proposal on the subsidies under the Affordable Care Act, popularly known as Obamacare, would have extended COVID-era subsidies for three years to keep insurance premiums from soaring for many. Without action by Congress, those premiums could more than double in cost on average, according to KFF, a health policy organization.
Sixty votes were needed to pass either measure in a Senate that Republicans control 53-47. Four Republicans voted for the Democratic proposal. No Democrats backed the Republicans’ bill.
President Donald Trump has largely sat out the brawl over health care, although he ultimately embraced the Cassidy-Crapo approach.
At Thursday’s bipartisan Congressional Ball, Trump predicted Republicans and Democrats would work together on health care. But he advocated for the Republican bill.
“We have an idea that rather than making these massive payments... insurance companies, we make beautiful big payments directly to the people, and they buy their own,” Trump said in remarks at the black-tie event at the White House.
The $1,500 payments in the Republican bill were meant to cover some of the out-of-pocket costs that people in the “Bronze” or “Catastrophic” categories — the lower-cost Obamacare plans — need to pay before their insurance kicks in.
However, it is far below the plans’ deductibles, meaning that even after that payment, a patient would be on the hook for up to $7,500 in out-of-pocket medical expenses before their insurance would start to pay for part of their care.
Those costs can rack up quickly for people with lower-cost plans, with a visit to a US emergency room costing between $1,000 and $3,000, while an ambulance ride can cost anywhere from $500 to over $3,500.
With 2026 congressional elections coming into focus, many Republicans are nervous about the prospect of stiff premium increases hitting every state, including many that backed Trump’s 2024 re-election. Polling indicates voters could mostly punish Republicans, who control Congress and the White House.
Republican US Senator Josh Hawley of Missouri, a state that Trump carried by 18 points in his 2024 re-election, said his constituents have been telling him, “We can’t afford our premiums now, let alone if they would go up by 50 or 100 percent.”
Insurance companies warned customers of the rising premiums in the new year, and Democrats argued there was not enough time to do anything but a clean extension of the tax credits they sought.
A new Reuters/Ipsos poll found Americans back a health care subsidy continuation. Some 51 percent of respondents — including three-quarters of Democrats and a third of Republicans — said they support extending the subsidies. Only 21 percent said they were opposed.
Moderate Republican Representative Brian Fitzpatrick of Pennsylvania is spearheading a bipartisan bill to extend the subsidy through 2027. He is hoping to garner enough support to circumvent leadership and force votes on the measure by the full House.
